BY SWFI INSTITUTE
COVID-19 is the most severe global pandemic since the influenza pandemic of 1918. A group of researchers discovered that COVID-19 (SARS-CoV-2) has a small piece of DNA that matched the genetic sequence patented by Moderna Inc. three years before the start of the pandemic in 2021. A Basic Local Alignment Search Tool (BLAST) search for the 12-nucleotide insertion led us to a 100% reverse match in a proprietary sequence (SEQ ID11652, nt 2751-2733) found in the U.S. patent 9,587,003 filed on February 4, 2016. In bioinformatics, BLAST is an algorithm and program for comparing primary biological sequence information, such as the amino-acid sequences of proteins or the nucleotides of DNA and/or RNA sequences. Moderna filed the patent as part of its cancer research division. COVID-19 is made up of 30,000 letters of genetic code that carry the information it needs to spread that are known as nucleotides. The commonality was a very small piece made up of 19 nucleotides. Analysis of the original COVID-19 genome found the virus shares a sequence of 19 specific letters with a genetic section owned by Moderna, which has a total of 3,300 nucleotides, according to the report.
The findings were published in Frontiers in Virology and the team includes Akhil Varshney from Dr Shroff Charity Eye Hospital in New Delhi. The study is titled, âMSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site.â
âThe matching code may have originally been introduced to the COVID-19 genome through infected human cells expressing the MSH3 gene,â wrote Dr Balamurali Ambati, from the University of Oregon, in the study.
